Ignite Creation Date:
2025-12-25 @ 2:24 AM
Ignite Modification Date:
2025-12-27 @ 11:50 PM
Study NCT ID:
NCT01116934
Status:
COMPLETED
Last Update Posted:
2016-03-24
First Post:
2010-05-03
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Cytokines in Papillon-Lefèvre Syndrome
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D010214', 'term': 'Papillon-Lefevre Disease'}], 'ancestors': [{'id': 'D007645', 'term': 'Keratoderma, Palmoplantar'}, {'id': 'D012873', 'term': 'Skin Diseases, Genetic'}, {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}, {'id': 'D007642', 'term': 'Keratosis'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'eickholz@med.uni-frankfurt.de', 'phone': '+49-69-6301', 'title': 'Prof. Dr. Peter Eickholz', 'phoneExt': '5642', 'organization': 'JWGUniversity'}, 'certainAgreement': {'piSponsorEmployee': True}}, 'adverseEventsModule': {'timeFrame': 'Patients were asked to report AEs from blood sampling if they occured.', 'eventGroups': [{'id': 'EG000', 'title': 'PLS Patients', 'description': '8 PLS patients (one female) from 6 families', 'otherNumAtRisk': 8, 'otherNumAffected': 0, 'seriousNumAtRisk': 8, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Healthy Controls', 'description': '9 healthy donors', 'otherNumAtRisk': 9, 'otherNumAffected': 0, 'seriousNumAtRisk': 9, 'seriousNumAffected': 0}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Serum Concentrations of Interleukin (IL)-1 Beta', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Papillon-Lefèvre Syndrome (PLS) Patients', 'description': '8 PLS patients (one female) from 6 families'}, {'id': 'OG001', 'title': 'Healthy Controls', 'description': '9 healthy donors'}], 'classes': [{'title': 'interleukin-1 beta', 'categories': [{'measurements': [{'value': '1100.00', 'groupId': 'OG000', 'lowerLimit': '896.21', 'upperLimit': '2572.10'}, {'value': '896.21', 'groupId': 'OG001', 'lowerLimit': '771.15', 'upperLimit': '2014.00'}]}]}, {'title': 'interleukin-6', 'categories': [{'measurements': [{'value': '65559', 'groupId': 'OG000', 'lowerLimit': '40365', 'upperLimit': '108260'}, {'value': '45734', 'groupId': 'OG001', 'lowerLimit': '34056', 'upperLimit': '66365'}]}]}, {'title': 'interferon-inducible protein-10', 'categories': [{'measurements': [{'value': '12902.5', 'groupId': 'OG000', 'lowerLimit': '8105.5', 'upperLimit': '15735.5'}, {'value': '11563', 'groupId': 'OG001', 'lowerLimit': '9164', 'upperLimit': '19758'}]}]}, {'title': 'interferon gamma', 'categories': [{'measurements': [{'value': '3704.5', 'groupId': 'OG000', 'lowerLimit': '2629.5', 'upperLimit': '4372.8'}, {'value': '3317.4', 'groupId': 'OG001', 'lowerLimit': '2538.5', 'upperLimit': '5487.8'}]}]}, {'title': 'interleukin-8', 'categories': [{'measurements': [{'value': '50520', 'groupId': 'OG000', 'lowerLimit': '29280', 'upperLimit': '79870'}, {'value': '44390', 'groupId': 'OG001', 'lowerLimit': '24680', 'upperLimit': '46580'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': '2006', 'description': "Concentrations of IL-8, IL-6, IP-10, interferon (IFN)-gamma, and IL-1 beta, in plasma/RPMI samples were determined by enzyme linked immunosorbent assay (ELISA) according to the manufacturers' instructions", 'unitOfMeasure': 'pg/ml', 'dispersionType': 'Inter-Quartile Range', 'reportingStatus': 'POSTED', 'populationDescription': 'Samples were stimulated with 100 ng/ml lipopolysaccharide (LPS)'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Papillon-Lefèvre Syndrome (PLS) Patients', 'description': '8 PLS patients (one female) from 6 families'}, {'id': 'FG001', 'title': 'Healthy Controls', 'description': '9 healthy donors'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '8'}, {'groupId': 'FG001', 'numSubjects': '9'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '8'}, {'groupId': 'FG001', 'numSubjects': '9'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '17', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'PLS Patients', 'description': '8 PLS patients (one female) from 6 families'}, {'id': 'BG001', 'title': 'Healthy Controls', 'description': '9 healthy donors'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '5', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '5', 'groupId': 'BG002'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '12', 'groupId': 'BG002'}]}, {'title': '>=65 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '7', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '16', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'Germany', 'categories': [{'measurements': [{'value': '8', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '17', 'groupId': 'BG002'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'CROSS_SECTIONAL', 'observationalModel': 'CASE_CONTROL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 17}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2006-07'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2016-02', 'completionDateStruct': {'date': '2009-12', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2016-02-23', 'studyFirstSubmitDate': '2010-05-03', 'resultsFirstSubmitDate': '2015-06-01', 'studyFirstSubmitQcDate': '2010-05-03', 'lastUpdatePostDateStruct': {'date': '2016-03-24', 'type': 'ESTIMATED'}, 'resultsFirstSubmitQcDate': '2016-02-23', 'studyFirstPostDateStruct': {'date': '2010-05-05', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2016-03-24', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2007-01', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Serum Concentrations of Interleukin (IL)-1 Beta', 'timeFrame': '2006', 'description': "Concentrations of IL-8, IL-6, IP-10, interferon (IFN)-gamma, and IL-1 beta, in plasma/RPMI samples were determined by enzyme linked immunosorbent assay (ELISA) according to the manufacturers' instructions"}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['blood culture, IL-1β, IL-6, IL-8, IP-10, interferon-gamma'], 'conditions': ['Papillon-Lefevre Disease']}, 'referencesModule': {'references': [{'pmid': '11338309', 'type': 'BACKGROUND', 'citation': 'Eickholz P, Kugel B, Pohl S, Naher H, Staehle HJ. Combined mechanical and antibiotic periodontal therapy in a case of Papillon-Lefevre syndrome. J Periodontol. 2001 Apr;72(4):542-9. doi: 10.1902/jop.2001.72.4.542.'}, {'pmid': '15111626', 'type': 'BACKGROUND', 'citation': 'Noack B, Gorgens H, Hoffmann T, Fanghanel J, Kocher T, Eickholz P, Schackert HK. Novel mutations in the cathepsin C gene in patients with pre-pubertal aggressive periodontitis and Papillon-Lefevre syndrome. J Dent Res. 2004 May;83(5):368-70. doi: 10.1177/154405910408300503.'}, {'pmid': '15857107', 'type': 'BACKGROUND', 'citation': 'Lux CJ, Kugel B, Komposch G, Pohl S, Eickholz P. Orthodontic treatment in a patient with Papillon-Lefevre syndrome. J Periodontol. 2005 Apr;76(4):642-50. doi: 10.1902/jop.2005.76.4.642.'}, {'pmid': '16970621', 'type': 'BACKGROUND', 'citation': 'Schacher B, Baron F, Ludwig B, Valesky E, Noack B, Eickholz P. Periodontal therapy in siblings with Papillon-Lefevre syndrome and tinea capitis: a report of two cases. J Clin Periodontol. 2006 Nov;33(11):829-36. doi: 10.1111/j.1600-051X.2006.00992.x. Epub 2006 Sep 13.'}, {'pmid': '18294227', 'type': 'BACKGROUND', 'citation': 'Noack B, Gorgens H, Schacher B, Puklo M, Eickholz P, Hoffmann T, Schackert HK. Functional Cathepsin C mutations cause different Papillon-Lefevre syndrome phenotypes. J Clin Periodontol. 2008 Apr;35(4):311-6. doi: 10.1111/j.1600-051X.2008.01201.x. Epub 2008 Feb 20.'}]}, 'descriptionModule': {'briefSummary': 'Papillon-Lefèvre syndrome (PLS) is characterised by aggressively progressive periodontitis combined with palmo-plantar hyperkeratosis. It is caused by "loss of function" mutations in the cathepsin C gene. The hypothesis behind this study is that PLS patients\' PMNs produce more proinflammatory cytokines to compensate for their reduced capacity to neutralize leukotoxin and to eliminate Aggregatibacter actinomycetemcomitans. Production of more interleukin (IL)-8 would result in the attraction of more PMNs. Thus, the aim of this study was to evaluate the cytokine profile in PLS patients\' blood cultures.', 'detailedDescription': "MATERIAL AND METHODS Materials Lipopolysaccharide (LPS; Escherichia coli, serotype R515) was purchased from Alexis (Lausen, Switzerland) and adenosine triphosphate (ATP) from Sigma (Deisenhofen, Germany). Tumor necrosis factor α (TNF-α) was kindly provided by the Knoll AG (Ludwigshafen, Germany). IL-1β was from Invitrogen/Biosource (Karlsruhe, Germany).\n\nPatients and healthy donors Five patients with established diagnose of PLS are under periodontal treatment at the Department of Periodontology, Center for Dental, Oral, and Maxillofacial Medicine (Carolinum) of the Johann Wolfgang Goethe-University Frankfurt am Main. Antiinfective therapy with adjunctive antibiotics has been rendered to all of them and they are under regular and frequent supportive therapy. The Department of Periodontology has contact to additional 5 PLS patients that are edentulous or under periodontal therapy elsewhere. All patients underwent complete oral examinations as well as inspection of the skin of the palms and soles. Each adult patient or parents received clinical and genetic counselling, and signed a consent form, approved by the ethic committees of the Universities of Dresden and Frankfurt/Main. Clinical data and mutations of all patients have been reported before. All these patients were invited to take part in this study. Healthy donors had abstained from taking drugs for two weeks prior to the study. Due to wide spread use of oral contraceptives only male probands were chosen. The study complied with the rules of the Declaration of Helsinki and was approved by the Institutional Review Board for Human Studies of the Medical Faculty of the Johann Wolfgang Goethe-University Frankfurt/Main (Application# 31/05). All participating individuals were informed on risks and benefit as well as the procedures of the study and gave written informed consent.\n\nWhole blood culture Heparinized blood was mixed with an equal volume of culture medium (RPMI 1640 supplemented with 25 mM HEPES (2-\\[4-(2-hydroxyethyl)piperazin-1-yl\\]ethanesulfonic acid), 100 U/ml penicillin, 100 µg/ml streptomycin) and 1 ml aliquots were transferred into loosely sealed round-bottom polypropylene tubes (Greiner, Germany). Whole blood cultures were kept at 37 oC and 5 % CO2 for the indicated time periods. Thereafter, cell-free plasma/RPMI samples were obtained by centrifugation and stored at -70oC until assessment of cytokine concentrations by enzyme linked immunosorbent essay (ELISA). Experiments were started within 60 min of blood withdrawal. Thus, the whole blood cultures consisted of the whole range of white blood cells as well as erythrocytes. Except for determination of IL-1β release, cultures were either kept as unstimulated control or stimulated with LPS (10 or 100 ng/ml), or with the combination of IL-1β plus TNF-α (50 ng/ml each) for 24h. For determination of IL-1β release, cells were kept as unstimulated control or were stimulated with Toll-like receptor 4 ligand LPS (100 ng/ml) for altogether 5h. For efficient release of IL-1β from activated cultures, LPS was combined with ATP (2 mM) which was added during the last 2h of the 5h stimulation period in order to achieve activation of the purinoreceptor P2X7.\n\nAnalysis of cytokine release by ELISA analysis Concentrations of IL-8, IL-6, interferon-inducible protein (IP)-10, interferon (IFN) gamma (Pharmingen/BD Biosciences), and IL-1β, (R\\&D Systems), in plasma/RPMI samples were determined by ELISA according to the manufacturers' instructions.\n\nStatistics The individual patient or proband was defined as statistical unit. Data are shown as median with interquartile range and are presented as pg/ml (IL-1β, IL-6, IP-10) or as ng/ml (IL-8). Medians were compared between PLS patients and healthy volunteers using the non parametric Mann Whitney U test. Statistical analysis was performed using a computer program (Systat for Windows version 10.0, Systat Inc., Evanston, IL, USA)."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': '5 patients with established diagnose of PLS are under periodontal treatment at the Department of Periodontology, Center for Dental, Oral, and Maxillofacial Medicine (Carolinum) of the JWG-University Frankfurt am Main. Antiinfective therapy with adjunctive antibiotics has been rendered to all of them and they are under regular and frequent supportive therapy. The Department of Periodontology has contact to additional 5 PLS patients that are edentulous or under periodontal therapy elsewhere.', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Diagnose of PLS\n\nExclusion Criteria:\n\n* No written informed consent'}, 'identificationModule': {'nctId': 'NCT01116934', 'briefTitle': 'Cytokines in Papillon-Lefèvre Syndrome', 'organization': {'class': 'OTHER', 'fullName': 'Goethe University'}, 'officialTitle': 'Observational Study on Cytokine Production by Leukocytes of Papillon-Lefèvre Syndrome Patients and Healthy Probands in Whole Blood Cultures', 'orgStudyIdInfo': {'id': 'PLS-Cytokines'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'PLS patients', 'description': 'Eight PLS patients (one female) from 6 families.'}, {'label': 'Healthy controls', 'description': 'Healthy donors had abstained from taking drugs for two weeks prior to the study. Due to wide spread use of oral contraceptives only male probands were chosen.'}]}, 'contactsLocationsModule': {'locations': [{'zip': '60596', 'city': 'Frankfurt am Main', 'country': 'Germany', 'facility': 'Department of Periodontology, Center for Dental, Oral, and Maxillofacial Medicine (Carolinum), JWG-University', 'geoPoint': {'lat': 50.11552, 'lon': 8.68417}}], 'overallOfficials': [{'name': 'Peter Eickholz, Prof. Dr.', 'role': 'STUDY_CHAIR', 'affiliation': 'JWG-University'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Goethe University', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Prof. Dr. med. dent.', 'investigatorFullName': 'Peter Eickholz', 'investigatorAffiliation': 'Goethe University'}}}}